Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 8/20 | 0.43 |
| ▸ | NOS1 | P29475 | 8/20 | 0.43 |
| ▸ | NOS2 | P35228 | 7/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699029 | 0.85 | NOS1 (0.41) | NOS3NOS1NOS2TLR8TLR7 | |
| SCHEMBL6703553 | 0.84 | NOS3 (0.46) | NOS3NOS1NOS2 | |
| SCHEMBL6699975 | 0.83 | NOS3 (0.46) | NOS3NOS1NOS2 | |
| SCHEMBL6699114 | 0.83 | NOS3 (0.45) | NOS3NOS1NOS2TLR8 | |
| SCHEMBL6702574 | 0.82 | NOS3 (0.44) | NOS3NOS1NOS2 | |
| SCHEMBL6702828 | 0.82 | NOS3 (0.45) | NOS3NOS1NOS2 | |
| SCHEMBL6697919 | 0.82 | NOS3 (0.45) | NOS3NOS1NOS2 | |
| SCHEMBL6697645 | 0.82 | NOS1 (0.60) | NOS3NOS1TLR8TLR7TLR9 | |
| SCHEMBL6618478 | 0.76 | NOS1 (0.69) | NOS3NOS1NOS2DRD2HTR2A | |
| SCHEMBL7480031 | 0.72 | MAP4K4 (0.47) | NOS3NOS1NOS2FEN1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | LOWE JOHN A (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1007512-B1 | BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS | PFIZER PROD INC (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6362195-B1 | INHIBITOR OF NITRIC OXIDE SYNTHASE; CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-03-26 | — | — | US | disclosed |
| US-20020022642-A1 | Branched alkoxy-subsituted 2-aminopyridines | LOWE JOHN ADAMS (US) | 2002-02-21 | — | — | US | disclosed |
| EP-1109556-A2 | NEW PHARMACEUTICAL USES FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-1007512-A1 | BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS | Pfizer Products Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-2000009130-A2 | NEW PHARMACEUTICAL USES FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-1999011620-A1 | BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022642-A1 | Branched alkoxy-subsituted 2-aminopyridines | NOS3, NOS2, PNMT | NOS3 1/4885NOS1 4/4885NOS2 2/4885 |
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | NOS1, NOS3, NOS2 | NOS3 2/4885NOS1 1/4885NOS2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.